胰腺癌组织微血管密度及淋巴管密度的改变及临床意义

目的：研究胰腺癌组织中微皿管密度（MVD）和淋巴管密度（LVD）的变化、与胰腺癌临床病理的联系及相互关系。方法：采用免疫组织化学SABC法应用CD34检测41例胰腺导管腺癌患者配对癌组织和正常胰腺组织中MVD的表达情况,应用D2—40检测配对癌组织、癌旁组织及正常胰腺组织中LVD的表达情况,分析MVD和LVD与肿瘤分化程度、分期和淋巴转移间的相关性以及癌组织MVD与癌旁组织LVD表达之间的关系。结果：癌组织及正常胰腺组织MVD分别为46585±16,935和11．100±4．036,两组差异有统计学意义（P=0．000）。癌组织、癌旁及正常胰腺组织LVD分别为11．244±4．800、15．829±7．470和13．512±5．139;其中癌旁组织与正常胰腺组织LVD差异无统计学意义（P=0．060）,癌旁组织与癌组织的LVD差异有统计学意义（P=0．000）。胰腺癌组织MVD与癌旁组织LVD间存在相关性（P=0.025〈0．05）。结论：胰腺导管腺癌组织中MVD及LVD与肿瘤分化程度、病理分期及淋巴转移相关;胰腺癌组织内MVD与癌旁组织LVD间存在相关性。     

组织因子的表达与人类胰腺癌组织学分级的关系

组织因子的表达与人类胰腺癌组织学分级的关系温州医学院附一医普外科余震摘张启瑜校作者研究发现细胞表面组织因子（ＴＦ）的染色可以作为胰腺癌病人的预后评价指标。材料和方法：标本分别来源于５５例胰腺导管腺癌和１８例正常胰腺组织，采用免疫组化法半定量测定的免疫...     

环状RNA-PCAC1促进胰腺导管腺癌侵袭转移的研究

目的探讨环状RNA（circRNA）-PCAC1在胰腺导管腺癌中的表达水平及其与患者临床病理特征、预后的关系。 方法鉴定circRNA-PCAC1，并通过功能实验观察其对胰腺导管腺癌侵袭转移能力的影响。采用RT-PCR检测76例胰腺导管腺癌组织与配对癌旁组织的circRNA-PCAC1表达水平，Cox回归模型和Kaplan-Meier曲线法分析circRNA-PCAC1与患者临床病理特征和预后的关系。 结果功能实验证实circRNA-PCAC1过表达显著促进胰腺导管腺癌侵袭转移能力。胰腺导管腺癌组织中circRNA-PCAC1的表达水平显著高于癌旁组织（P<0.01）。circRNA-PCAC1过表达与胰腺导管腺癌患者不良预后相关（P<0.05）。circRNA-PCAC1是胰腺导管腺癌患者总生存期（HR=1.733，95% CI：1.066~2.991，P=0.030）和无病生存期（HR=1.636，95% CI：1.090~2.811，P=0.042）的独立影响因素。 结论circRNA-PCAC1在胰腺导管腺癌中高表达并促进胰腺导管腺癌侵袭转移，提示其可能成为胰腺导管腺癌临床治疗的新靶点。     

TRPM8在胰腺导管腺癌中的表达及意义

目的 检测TRPM8在胰腺导管腺癌中的表达情况并分析其临床意义.方法 收集我院肝胆外科自2008年至2010年40例行手术切除的胰腺导管腺癌病例的临床病理资料,分别采用实时荧光定量PCR（Real-Time PCR）、免疫组织化学和Western blotting的方法检测TRPM8 mRNA和蛋白水平的表达情况,并分析其与各临床病理参数之间的关系.结果 TRPM8在mRNA和蛋白水平表达一致.TRPM8mRNA在胰腺导管腺癌患者癌组织中表达明显高于正常组织[（0.0512±0.0498）vs （0.0008±0.0005）,P＜ 0.05].单因素和多因素分析发现TRPM8的表达是一个独立的预后因素.2年无病生存率和总生存率,TRPM8阳性染色组明显低于阴性染色组（48％ vs 18％,58％ vs 22％）,差异具有统计学意义（P＜ 0.05）.临床病理特征评估结果：TRPM8的高表达与胰腺导管腺癌组织的分化程度、TNM分期及淋巴结转移之间存在显著性相关（P＜0.05）,与肿瘤大小、患者年龄、性别等无关.结论 TRPM8在胰腺导管腺癌中表达上调并与一些临床病理特征密切相关,提示TRPM8可能是反映胰腺导管腺癌发生发展、侵袭、转移及预后的重要生物学指标.     

原位PCR检测胰腺癌中TGF—βmRNA的表达及意义

目的 研究TGF－β1在胰导管癌中的表达及意义。方法 采用RT－PCR、原位PCR杂交技术检测23例胰导管腺癌和4例正常胰腺组织中TGF-βmRNA的表达。结果 正常胰腺组织中无TGF－β1的表达。胰腺癌组织中TGF-βmRNA表达率为69．6％（16／23）,原位PCR杂交显示其表达位于胰腺癌细胞膜上,TGF－β1表达程度与肿瘤的病理分期、淋巴结转移有明显的相关性（P＜0．05）。TGF－β1阳性者1年生存率为13．3％（2／15）,明显低于阴性者（5／6）。结论 TGF－β1与胰腺癌的病理分期、预后相关,临床检测可用于评估其生物学行为。     

胰腺癌组织SOX9的表达水平与肿瘤进展及预后的关系

目的 探究胰腺导管腺癌（pancreatic ductal adenocarcinoma,PDAC）中SOX9的表达水平及临床病理学意义.方法对 正常胰腺、胰腺导管内乳头状黏液瘤（IPMN）、胰腺上皮内瘤样病变（PanIN）及PDAC标本进行免疫组织化学染色,观察SOX9在不同胰腺组织中的表达情况,并将62例手术切除的PDAC组织标本的染色结果同临床病理及预后资料进行对比分析.最后对三种不同分化水平的胰腺癌细胞株做免疫荧光染色及qRT-PCR,检测其SOX9阳性细胞表达比率及SOX9mRNA表达水平.结果 免疫组织化学结果显示：SOX9蛋白在正常胰腺、IPMN、PanIN及PDAC组织中均呈阳性表达.SOX9蛋白表达水平与PDAC肿瘤浸润深度、淋巴结转移呈正相关.SOX9蛋白高表达PDAC病人较低表达者预后差.体外实验免疫荧光染色及qRT-PCR结果显示,在低分化胰腺癌细胞株PANC-1,SOX9阳性细胞比率及SOX9 mRNA表达水平明显高于高分化细胞株CA-PAN-2及中分化细胞株BxPC-3.结论 在PDAC中SOX9表达上调,与肿瘤进展及不良的预后相关,SOX9可能作为评估PDAC病人预后的指标.     

甲基化CpG结合域蛋白1在胰腺癌组织中的表达和意义

目的：检测甲基化CpG结合域蛋白I（MBD1）蛋白在胰腺癌组织中的表达，并探讨其临床意义。方法：应用S-P免疫组织化学法检测38例胰腺癌、17例胰腺癌旁组织、8例胰腺良性肿瘤、3例慢性胰腺炎和6例正常胰腺组织中MBD1蛋白的表达。结果：MBD1在胰腺癌组织、正常胰腺组织、胰腺良性肿瘤、胰腺癌旁组织中的表达阳性率分别是76．32％（29/38）、16．67％（1／6）、25．0％（2／8）、29．41％（5／17），3例慢性胰腺炎标本中未见表达；胰腺癌阳性表达率明显高于正常胰腺、慢性炎症、良性肿瘤和癌旁对照组织（P〈0．05）。MBD1表达水平的高低与病人的性别、年龄、肿瘤部位、肿瘤大小、分化程度和TNM分期无显著性差异（P〉0．05）；而与淋巴结转移密切相关，有淋巴结转移者胰腺癌组织MBD1的表达阳性率为92．31％（24／26），高于无淋巴结转移者的41．67％（5／12）（P〈0．01）。结论：胰腺癌中MBD1呈高水平表达，并与胰腺癌的高转移侵袭活性有关，其机制可能与MBD1介导抑制多个甲基化相关抑癌基因的表达有关。MBD1的转录调控机制有待进一步研究。     

TGFa在胰腺癌中的表达及其与癌细胞DNA倍型的关系

目的 研究胰腺癌中TGFa的表达及其与癌细胞DNA倍型的关系.方法 分别采用TGFa单抗免疫染色及Feulgen染色法对67例胰腺导管腺癌和16例正常胰腺进行染色,并分析TGFa表达与癌细胞DNA倍型的关系.结果 胰腺癌组织TGFa染色阳性率为41.8%,正常胰腺组织中未见阳性染色.TGFa阳性胰腺癌癌细胞异倍体率为89.3%,明显高于阴性组.结论TGFa表达与胰腺癌发生及癌细胞核增殖活性有关.     

原位PCR检测胰腺癌中TGF-β1mRNA的表达及意义

目的研究TGF-β1在胰导管腺癌中的表达及意义.方法采用RT-PCR、原位PCR杂交技术检测23例胰导管腺癌和4例正常胰腺组织中TGF-β1mRNA的表达.结果正常胰腺组织中无TGF-β1的表达.胰腺癌组织中TGF-β1 mRNA表达率为69.6%(16/23),原位PCR杂交显示其表达位于胰腺癌细胞膜上,TGF-β1表达程度与肿瘤的病理分期、淋巴结转移有明显的相关性(P＜0.05).TGF-β1阳性者1年生存率为13.3%(2/15),明显低于阴性者(5/6).结论TGF-β1与胰腺癌的病理分期、预后相关,临床检测可用于评估其生物学行为.     

Ezrin在胰腺癌和胰腺囊腺瘤中的表达及其意义

目的：探讨Ezrin在正常胰腺组织、胰腺癌组织及胰腺囊腺瘤中的表达及其表达与胰腺癌侵袭转移的关系。方法：用两步免疫组织化学染色法检测13例正常胰腺, 34例胰腺癌及24例胰腺囊腺瘤组织中Ezrin的表达。结果：Ezrin在正常胰腺、胰腺囊腺瘤及胰腺癌的细胞膜强阳性表达率分别为0%, 12.5%和32.4%, 各组织中Ezrin的表达差异均有统计学意义(P＜0.05)。Ezrin表达强度与肿瘤分化程度、临床分期和有无淋巴结转移有关(P＜0.05)。结论：Ezrin在细胞膜的高表达与胰腺癌的发生及侵袭转移关系密切, Ezrin可能是影响胰腺癌患者预后及癌细胞转移的一个重要因素。     

Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer.

OBJECTIVES: E-cadherin and its associated intracellular molecules, catenins, are important for cell-cell adhesion. Impaired expression of these molecules are frequently observed in several cancers. E-cadherin and beta-catenin are often expressed in non-small cell lung cancers. The aim of this study was to investigate the expressions of E-cadherin and beta-catenin and their significance as prognostic markers in pathological stage I non-small cell lung cancer. METHODS: Paraffin embedded tumor tissue blocks were obtained from 141 patients who underwent resection without preoperative radiotherapy or chemotherapy with pathological stage I non-small cell lung cancer. Tumor samples were prepared in tissue microarrays and they were stained by immunohistochemistry with antibodies against E-cadherin and beta-catenin. The expressions of E-cadherin and beta-catenin were analyzed with relation to the clinico-pathological data. The median follow-up period of the patients was 41 months (range, 2-88 months). RESULTS: Preserved expressions of E-cadherin and beta-catenin were observed in the membrane and the cytoplasm of normal epithelial cells and tumor cells. Absent or reduced expression for E-cadherin and beta-catenin were observed in 60% and 45% of all the patients, respectively. There was a significant positive correlation between E-cadherin and beta-catenin expression (P<0.01). Absent or reduced expression of E-cadherin was observed in 72.5%, 36.6%, and 60.0% of squamous cell carcinoma, adenocarcinoma, and bronchioloalveolar carcinoma, respectively. There was a significant decrease of E-cadherin expression in squamous cell carcinoma compared to adenocarcinoma (P<0.01). Patients with reduced expression of beta-catenin had poor recurrence free survival in adenocarcinoma, but not in squamous cell carcinoma. CONCLUSION: Decreased expressions of E-cadherin and beta-catenin were closely correlated in resected stage I non-small cell lung cancer. Reduced expression of E-cadherin and beta-catenin indicates tumor cell dedifferentiation and reduced expression of beta-catenin had poor recurrence free survival in adenocarcinoma of the resected stage I non-small cell lung cancer.     

Slug在胰腺癌中的表达及干扰Slug对胰腺癌转移的影响

目的 探讨Slug和E-CADHERIN(E-cadherin)表达与胰腺癌转移的关系以及干扰Slug转录因子对胰腺癌转移的影响.方法 采用免疫组化和RT-PCR技术分别检测36例胰腺癌组织中Slug、E-cadherin和mRNA表达.将肝脏高转移潜能的胰腺癌细胞株SW1990H4,分为3组:对照组、空载体质粒(shRNA-1)和转染干扰S1ug质粒(Slug-shRNA-1),观察Slug对E-cadherin mRNA表达的逆转作用,及对SW1990H4体外侵袭、运动的抑制作用.结果 胰腺癌组织中Slug高表达,而E-cadherin低表达.转移组胰腺癌组织中Slug蛋白和mRNA表达明显高于非转移组,差异分别有统计学意义(P＜0.05),而E-cadherin在转移组胰腺癌中无表达.PCR产物凝胶电泳结果显示,Slug mRNA在空白对照组SW1990H4中表达为0.985±0.016,E-cadherin mRNA表达为0.120±0.001.shRNA-1时转染48 h时,Slug mRNA的表达水平为0.973±0.014,E-cadherin mRNA表达水平分别0.160±0.001,与对照组比差异分别无统计学意义(P＞0.05).转染Slug-shRNA-1组瞬时转染48 h时,Slug mRNA的表达水平为0.554±0.011,E-cadherin mRNA表达水平为0.36±0.002,与对照组和shRNA-1组比差异分别有统计学意义(P＜0.05).SW1990H4稳定转染后,shRNA-1和Slug-shRNA-1组Slug mRNA表达水平分别为0.968±0.015,0.206±0.017,两组比较,差异有统计学意义(P＜0.05),而E-cadherin mRNA表达水平分别为0.18±0.002,0.727±0.006,两组比较,差异有统计学意义(P＜0.05).体外细胞运动实验表明,对照组、转染shRNA-1和SlugshRNA-1组跨膜细胞数393±28、352±24、96±13,差异有统计学意义(P＜0.01).重组细胞基底膜(Matrige1)侵袭实验显示,3组穿透基底膜细胞数分别为223±69、202±64、65±19,差异有统计学意义(P＜0.05).结论 Slug高表达,E-cadherin低表达与胰腺癌的转移相关.胰腺癌细胞中存在Slug mRNA与E-cadherin mRNA表达的逆转关系,抑制Slug mRNA的表达对胰腺癌细胞的侵袭和运动有抑制作用,可能为胰腺癌转移的基因治疗提供新的靶点.

Abstract：

Objective To investigate expression of slug and E-cadherin in pancreatic cancer tissues and determine the inhibitory effects of anti-Slug, an anti-sense plasmid, on the invasion of pancreatic cancer cell lines in vitro. Methods Slug and E-cadherin protein and mRNA was analyzed by IHP and RT-PCR in 36 cases of pancreatic cancer. Then anti-Slug plasmid was transfected into herin and Slug expression. The inhibitory effects of anti-sense Slug were also detected by Transwell motility assay and Matrigel invasion assay. Results The expression of Slug and mRNA in metastatic pancreatic cancer tissue was higher than that in non-metastatic tissue. E-cadherin and mRNA was lower in metastasis tissues(P＜0.05). The inverse relationships were further observed by transient transfection of anti-Slug into SW1990H4 cells. The downregulated expression of Slug and re-expression of E-cadherin were found. The Slug mRNA levels were 0.985±0.016,0.973±0.014, 0. 554±0. 011 after 0, 48 h of transfection of anti-sense Slug, and that of E-cadherin were 0.120±0.001, 0.360±0.002, 0. 727±0. 006, respectively. The diference was significant between different time points (P＜0.05). The Slug mRNA levels were 0. 206±0.017, 0.968±0.015, and that of E-cadherin were 0. 18±0.002,0.727±0.006 after stable transfection of anti-sense Slug, and control plasmid, respectively. The diference was significant (P＜0.05). The motility activity(393±28, 352±24, 96 ±13 )and the invasion activity (223 ± 69, 202 ± 64, 65 ±19) of1 antisense Slug transfectant cells were significantly decreased as compared with those of control cells (P＜0.05). Conclusions Higher expression of slug and lower expression of E-cadherin is related to the invasion and metastasis in pancreatic cancer. A reverse corelation of E-cadherin and Slug expression exists in pancreatic cancer. Slug is possibly a potential target for cancer gene therapy blocking invasion and metastasis in human pancreatic cancer.     

EphA2/EphrinAl及E-cadherin在胰腺癌中的表达及临床意义

目的 探讨EphA2、EphrinAl及E-cadherin在胰腺癌及癌旁非肿瘤组织中的表达及临床意义.方法.采用免疫组织化学EnVision二步法,检测48例胰腺癌及癌旁非肿瘤胰腺组织中EphA 2、EphrinAl和E-cadherin的表达,并分析其与临床病理因素的关系.应用log-rank检验和Cox比例风险模型分析EphA 2、EphrinAl和E-cadherin的表达与患者预后的关系.结果 EphA 2、EphrinAl和E-cadherin在胰腺癌组织和癌旁非肿瘤组织阳性表达差异均有统计学意义.Ⅲ～Ⅳ期胰腺癌EphA 2、EphrinAl强阳性染色及E-cadherin阴性染色分别为47.9%、47.9%和64.6%,显著高于Ⅰ～Ⅱ期的6.25%、8.3%和14.6%(P<0.05).E-cadherin表达阳性与阴性患者术后生存率比较差异有统计学意义(P<0.05).Cox多因素分析表明,JPS分期、EphA 2阳性表达及E-cadherin阴性表达是反映胰腺癌预后的独立指标.结论 EphA2/EphrinAl与E-cadherin蛋白表达异常可能共同参与了胰腺癌的发生、发展与转移;联合检测三种蛋白对于评价胰腺癌的预后有一定参考价值.

Abstract：

Objective To investigate the relationship between EphA2, EphrinAl and E-cadherin expressions and tumor stage and prognosis in pancreatic cancer. Method EphA2, EphrinAl and Ecadherin expressions were detected by immunohistochemistry in the tumor tissue and normal tissue specimens from 48 patients with primary pancreatic cancer. Results The expressions of EphA2 and EphrinAl were higher in the pancreatic carcinoma tissues than in the normal pancreatic tissues (P<0. 05). The E-cadherin expression was lower in the pancreatic cancer tissues than in the normal pancreatic tissues (P<0. 05). With decreasing histological differentiation, the expressions of EphA2 and EphrinAl in carcinoma tissues increased significantly (P<0. 05), while the E-cadherin expression decreased significantly (P<0. 05). The positive expressions of EphA2 and EphrinAl in the primary tumor significantly increased in stageⅢ and Ⅳ than in stage Ⅰ and Ⅱ (47. 9%vs 6. 25% , P<0. 05;47. 9% vs 8. 3%, P<0. 05), while the negative expression of E-cadherin was reversely correlated with these tumor stages (14. 6% vs 64. 6%, P<0. 05). Cox multivariate analysis showed that the clinical stage, EphA2 positive expression and E-cadherin negative expression were significantly associated with survival. Conclusion Abnormal expressions of EphA2, EphrinAl and E-cadherin were involved in the progression of pancreatic cancer and they were useful in predicting prognosis.     

E-cadherin和Slug在胃癌组织中的表达及意义

目的：探讨胃癌患者肿瘤组织中E-cadherin及Slug的表达与肿瘤病理特征及预后的关系。方法：免疫组化检测82例胃癌患者瘤组织E-cadherin及Slug的表达,并分析它们与患者的病理特征及生存时间的关系。结果：E-cadherin保留表达率为47.6%,Slug阳性表达率为39.0%。E-cadherin的表达率差异与患者的N分期有关,Slug的阳性表达率差异与患者的性别、T分期及N分期有关（均P<0.05）;在E-cadherin表达保留组,Slug的表达与N分期、M分期、静脉侵袭、血行性转移和腹膜复发有关,而在E-cadherin表达降低组,Slug的表达与T分期有关（均P<0.05）;E-cadherin表达保留患者5年生存率高于E-cadherin表达降低患者（79.5% vs. 60.5%）,Slug阳性患者的5年生存率低于Slug阴性患者（59.4% vs. 74.0%）（均P<0.05）;E-cadherin表达保留组中,Slug阳性患者5年生存率低于阴性患者分别为（48.4% vs. 87.5%）（P<0.05）,而E-cadherin表达降低组中,Slug阳性及阴性患者生存率无统计学差异（58.3% vs. 68.4%）（P>0.05）。结论：E-cadherin及Slug的表达主要与胃癌TNM分期有关;E-cadherin表达保留的患者中Slug的阳性表达对不良预后有预测意义。

     

EphA2与E cadherin在胰腺癌中的表达及其意义

目的 探讨EphA2和E-adherin在胰腺癌组织及细胞中的表达及其临床意义。方法 采用免疫组织化学SP方法，检测56例胰腺癌及23例癌旁非肿瘤胰腺组织中EphA2和E-cadherin的表达，并分析其与临床病理因素的关系。采用RT-PCR方法检测EphA2在胰腺癌细胞株BXPC-3，PC-3及PANC-1中的表达。结果 胰腺癌组织中EphA2阳性和E-cadherin阴件的表达率分别为66．07％和57．14％，均显著高于癌旁非肿瘤胰腺组织（P〈0．05）；EphA2表达与胰腺癌分化程度、TNM分期和淋巴结转移有关，E-adherin表达与胰腺癌TNM分期和淋巴结有关。在胰腺癌组织中，EphA2与E-cadherin的表达呈负相关；EphA2在胰腺癌向侵袭力细胞株BXPC-3和PANC-1呈高表达，在低侵袭力细胞PC-3呈低表达。结论 EphA2与E-cadherin的表达和／或功能异常可能共同参与胰腺癌的发生发展与转移；联合检测两种蛋白对于胰腺癌转移潜能的判断具有一定的参考价值。     

Prognostic significance of dysadherin expression in patients with non-small cell lung cancer

OBJECTIVE: The aim of this study was to evaluate the expression of dysadherin and E-cadherin and to investigate their clinical significance as prognostic factors in non-small cell lung cancer. METHODS: Non-small cell lung cancer specimens were obtained from 131 patients undergoing clinically indicated operations at the Department of General and Cardiothoracic Surgery, Kanazawa University Hospital, between 1995 and 1997. All patients had undergone curative resection of the primary tumor, including systematic lymph node dissection. The avidin-biotin-peroxidase complex method was used for immunostaining of dysadherin and E-cadherin. RESULTS: Among the 131 lung cancer specimens, 46 (35.1%) tumors were positively stained with dysadherin. Preserved membranous E-cadherin staining was present in 45.8% (60/131) of cases. In this analysis dysadherin expression was not correlated with E-cadherin expression (P = .1333), but a significant association was observed between dysadherin expression and survival time. The overall survival of patients with dysadherin-positive tumors was significantly worse than that of those with dysadherin-negative tumors (P = .0059). Patients with reduced E-cadherin immunopositivity survived significantly shorter than those with preserved E-cadherin immunopositivity (P = .0406). The overall survival of patients with positive dysadherin and reduced E-cadherin expression was significantly worse than that of patients with negative dysadherin and preserved E-cadherin expression (P = .0002). Multivariate analysis revealed the independent prognostic value of dysadherin positivity, reduced E-cadherin expression, and lymph node metastasis on overall survival. CONCLUSIONS: Dysadherin expression is an independent prognostic factor of survival in patients with non-small cell lung cancer, and combined immunohistochemical analysis of dysadherin and E-cadherin expression might provide further prognostic information.     

E-cadherin和nm23-H1的表达及其临床意义在胰腺癌

目的探讨上皮细胞钙黏蛋白（E-cadherin）和转移抑制基因（nm23-H1）表达与胰腺癌侵袭转移的关系。方法应用免疫组织化学技术SP法，检测31例癌组织中E-cadherin和nm23-H1的表达水平。结合肿瘤的侵袭转移能力、分化程度和分期等进行分析。结果31例胰腺癌组织中E-cadherin和nm23-H1的表达强度均低于对照的胰腺组织；E-cadherin和nm23-H1的表达强度与胰腺癌的远处转移能力密切相关；胰腺癌中E-cadherin和nm23-H1的表达具有明显正相关。结论E-cadherin和nm23-H1的表达水平能反映胰腺癌的侵袭转移能力。两种蛋白的表达水平之间呈明显正相关。联合检测两种蛋白在胰腺癌组织中的表达，对临床判断胰腺癌的预后可能有一定的意义。     

CTHRC1在胰腺癌中的表达及其意义

目的:观察胶原三股螺旋重复蛋白1(CTHRC1)在胰腺癌组织中的表达及其对胰腺癌细胞生物学行为的影响。方法:采用实时定量PCR(RT-PCR)方法检测40例胰腺患者癌组织与癌旁组织中CTHRC1的表达。胰腺癌Panc28细胞转染pcDNA3.1-CTHRC1或CTHRC1 siRNA后,以未转染的Panc28细胞为对照,采用克隆形成实验检测CTHRC1对胰腺癌Panc28细胞增殖,伤口愈合实验和Boyden小室检测细胞迁移和侵袭能力。结果:RT-PCR结果显示,胰腺癌组织CTHRC1 mRNA表达水平明显高于癌旁组织(P0.05)。与对照组Panc28细胞比较,转染pcDNA3.1-CTHRC1上调CTHRC1后,Panc28细胞克隆形成数明显增加、伤口宽度百分比明显减少、侵袭的细胞数明显增多,而转染CTHRC1 siRNA下调CTHRC1表达后,Panc28细胞以上指标呈反向变化,差异均有统计学意义(均P0.05)。结论:胰腺癌组织在CTHRC1表达升高,CTHRC1可能通过促进胰腺癌细胞的增殖、迁移和侵袭能力而参与胰腺癌的发生与发展。     

Lipocalin-2 is Associated With a Good Prognosis and Reversing Epithelial-to-Mesenchymal Transition in Pancreatic Cancer

Background

Lipocalin-2 is a multifaceted modulator in cancer progression. Its clinical significance is not clear in pancreatic cancer. The purpose of this study was to investigate whether lipocalin-2 is associated with good prognosis by reversing epithelial-to-mesenchymal transition (EMT) in pancreatic cancer.

Methods

Lipocalin-2, E-cadherin, or vimentin expression was detected in 60 pancreatic adenocarcinoma specimens. Correlations between lipocalin-2 expression and EMT, the clinicopathologic characteristics, and prognosis were investigated. Whether pancreatic cancer cells’ migration and invasion (some characteristics of EMT) were affected by lipocalin-2 was also explored.

Results

High lipocalin-2 expression was significantly associated with a good prognosis in pancreatic cancer (p < 0.05). Overexpression of lipocalin-2 correlated with a lower extent of EMT (p < 0.05), increased E-cadherin expression (p < 0.05), decreased vimentin expression (p < 0.05), and reduced cancer cell migration and invasion in pancreatic cancer.

Conclusions

Lipocalin-2 may be considered an epithelial inducer, which may reverse EMT and predict a good prognosis in pancreatic cancer.     

基于Sestrin2通过mTOR信号通路调节胰腺癌上皮-间质转化过程的实验研究

目的 探讨Sestrin 2在胰腺癌上皮-间质转化（EMT）过程中的作用。方法 对胰腺癌细胞PANC-1和CFPAC-1进行Sestrin 2表达干预,通过划痕试验、Transwell试验、RT-PCR、Western blotting和动物实验检测不同Sestrin 2表达水平下胰腺癌EMT过程的变化。同时,分析Sestrin 2在人体中的表达情况。结果 在Transwell试验和划痕试验中,高表达Sestrin 2胰腺癌细胞组的迁移能力和侵袭能力显著降低（P＜0.05）;在动物负瘤实验中,高表达Sestrin 2胰腺癌细胞组所生长的肿瘤更小（P＜0.05）;在RT-PCR和 Western blotting实验中,高表达Sestrin 2胰腺癌细胞组的E-钙黏蛋白表达水平增加（P＜0.05）,N-钙黏蛋白和波形蛋白表达水平下降（P＜0.05）。同时,Sestrin 2在人体胰腺癌中呈低表达;随着Sestrin 2表达水平的提高,mTOR信号通路中的关键分子p60-s6k表达水平明显降低（P＜0.05）。结论 Sestrin 2可抑制胰腺癌EMT过程,并可能通过mTOR信号通路发挥作用。